Current concepts in the biochemical assessment of the patient with acromegaly (Q35197916)

7 August 2017

1 reference

title

Current concepts in the biochemical assessment of the patient with acromegaly (English)

1 reference

7 August 2017

1 reference

Pamela U Freda

1

1 reference

7 August 2017

language of work or name

1 reference

1 August 2003

1 reference

Growth Hormone & I G F Research

7 August 2017

published in

1 reference

7 August 2017

volume

13

1 reference

7 August 2017

issue

4

1 reference

7 August 2017

page(s)

171-184

1 reference

Nutritional regulation of IGF-I and IGF binding proteins

7 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1096-6374%2803%2900029-7

7 January 2021

Determination of free insulin-like growth factor-I in human serum: comparison of ultrafiltration and direct immunoradiometric assay.

1 reference

https://api.crossref.org/works/10.1016%2FS1096-6374%2803%2900029-7

7 January 2021

6 Factors controlling blood concentration of somatomedin C

1 reference

https://api.crossref.org/works/10.1016%2FS1096-6374%2803%2900029-7

7 January 2021

Somatotropin pulse frequency and basal concentrations are increased in acromegaly and are reduced by successful therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1096-6374%2803%2900029-7

7 January 2021

Therapy of acromegaly with sandostatin: the predictive value of an acute test, the value of serum somatomedin-C measurements in dose adjustment and the definition of a biochemical 'cure'

1 reference

https://api.crossref.org/works/10.1016%2FS1096-6374%2803%2900029-7

7 January 2021

Characterization of 24-hour growth hormone secretion in acromegaly: implications for diagnosis and therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1096-6374%2803%2900029-7

7 January 2021

Relationship between somatomedin-C and growth hormone levels in acromegaly: basal and dynamic evaluation

1 reference

https://api.crossref.org/works/10.1016%2FS1096-6374%2803%2900029-7

7 January 2021

Plasma insulin-like growth factor-I/somatomedin-C in acromegaly: correlation with the degree of growth hormone hypersecretion

1 reference

https://api.crossref.org/works/10.1016%2FS1096-6374%2803%2900029-7

7 January 2021

Inter-relations between growth hormone, insulin, insulin-like growth factor-l (IGF-I), IGF-binding protein-1 (IGFBP-1) and sex hormone-binding globulin in acromegaly

1 reference

https://api.crossref.org/works/10.1016%2FS1096-6374%2803%2900029-7

7 January 2021

The importance of insulin-like growth factor (somatomedin) measurements in the diagnosis and surveillance of acromegaly

1 reference

https://api.crossref.org/works/10.1016%2FS1096-6374%2803%2900029-7

7 January 2021

Relationships between insulin-like growth factor-1 levels and growth hormone concentrations during diurnal profiles and following oral glucose in acromegaly.

1 reference

https://api.crossref.org/works/10.1016%2FS1096-6374%2803%2900029-7

7 January 2021

Gender and age in the biochemical assessment of cure of acromegaly

1 reference

https://api.crossref.org/works/10.1016%2FS1096-6374%2803%2900029-7

7 January 2021

Assessment of GH status in acromegaly using serum growth hormone, serum insulin-like growth factor-1 and urinary growth hormone excretion.

1 reference

https://api.crossref.org/works/10.1016%2FS1096-6374%2803%2900029-7

7 January 2021

IGFBP‐3 is a poor parameter for assessment of clinical activity in acromegaly

1 reference

https://api.crossref.org/works/10.1016%2FS1096-6374%2803%2900029-7

7 January 2021

Diagnostic value of serum IGF-I and IGFBP-3 in growth hormone disorders in adults

1 reference

https://api.crossref.org/works/10.1016%2FS1096-6374%2803%2900029-7

7 January 2021

Somatomedin-C levels in treated and untreated patients with acromegaly.

1 reference

https://api.crossref.org/works/10.1016%2FS1096-6374%2803%2900029-7

7 January 2021

Evaluation of Acromegaly by Radioimmunoassay of Somatomedin-C

1 reference

https://api.crossref.org/works/10.1016%2FS1096-6374%2803%2900029-7

7 January 2021

Investigation of the criteria for assessing the outcome of treatment in acromegaly

1 reference

https://api.crossref.org/works/10.1016%2FS1096-6374%2803%2900029-7

7 January 2021

Acromegaly with 'normal' serum growth hormone levels. Clinical features, diagnosis and results of transsphenoidal microsurgery

1 reference

https://api.crossref.org/works/10.1016%2FS1096-6374%2803%2900029-7

7 January 2021

https://api.crossref.org/works/10.1016%2FS1096-6374%2803%2900029-7

1 reference

7 January 2021

Long-term treatment of acromegaly with pegvisomant, a growth hormone receptor antagonist

1 reference

https://api.crossref.org/works/10.1016%2FS1096-6374%2803%2900029-7

7 January 2021

Somatomedin C in treated acromegaly: poor correlation with growth hormone and clinical response

1 reference

https://api.crossref.org/works/10.1016%2FS1096-6374%2803%2900029-7

7 January 2021

Bromocriptine therapy in acromegaly: use in patients resistant to conventional therapy and effect on serum levels of somatomedin C

1 reference

https://api.crossref.org/works/10.1016%2FS1096-6374%2803%2900029-7

7 January 2021

Bromocriptine therapy in acromegaly: effects on plasma GH levels, somatomedin-C levels and clinical activity

1 reference

https://api.crossref.org/works/10.1016%2FS1096-6374%2803%2900029-7

7 January 2021

Changes in circulating somatomedin-C levels in bromocriptine-treated acromegaly

1 reference

https://api.crossref.org/works/10.1016%2FS1096-6374%2803%2900029-7

7 January 2021

Evaluation of disease activity by IGF-I and IGF binding protein-3 (IGFBP3) in acromegaly patients distributed according to a clinical score

1 reference

https://api.crossref.org/works/10.1016%2FS1096-6374%2803%2900029-7

7 January 2021

Comparative study of insulin-like growth factor-I (IGF-I) and IGF-binding protein-3 (IGFBP-3) level and IGF-I/IGFBP-3 ratio measurements and their relationship with an index of clinical activity in the management of patients with acromegaly.

1 reference

https://api.crossref.org/works/10.1016%2FS1096-6374%2803%2900029-7

7 January 2021

Cardiovascular effects of depot long-acting somatostatin analog Sandostatin LAR in acromegaly.

1 reference

https://api.crossref.org/works/10.1016%2FS1096-6374%2803%2900029-7

7 January 2021

Is the acromegalic cardiomyopathy reversible? Effect of 5-year normalization of growth hormone and insulin-like growth factor I levels on cardiac performance

1 reference

https://api.crossref.org/works/10.1016%2FS1096-6374%2803%2900029-7

7 January 2021

Long-term mortality after transsphenoidal surgery and adjunctive therapy for acromegaly.

1 reference

https://api.crossref.org/works/10.1016%2FS1096-6374%2803%2900029-7

7 January 2021

Long-term outcome and mortality after transsphenoidal adenomectomy for acromegaly

1 reference

https://api.crossref.org/works/10.1016%2FS1096-6374%2803%2900029-7

7 January 2021

NIH conference. Insulin-like growth factors in health and disease

1 reference

https://api.crossref.org/works/10.1016%2FS1096-6374%2803%2900029-7

7 January 2021

Insulin-like growth factors in the fed and fasted states.

1 reference

https://api.crossref.org/works/10.1016%2FS1096-6374%2803%2900029-7

7 January 2021

Acromegaly with a misleading normal plasma insulin-like growth factor 1.

1 reference

https://api.crossref.org/works/10.1016%2FS1096-6374%2803%2900029-7

7 January 2021

Normal values of insulin-like growth factor I and their clinical utility in adults

1 reference

https://api.crossref.org/works/10.1016%2FS1096-6374%2803%2900029-7

7 January 2021

Serum insulin-like growth factor I in a random population sample of men and women: relation to age, sex, smoking habits, coffee consumption and physical activity, blood pressure and concentrations of plasma lipids, fibrinogen, parathyroid hormone an

1 reference

https://api.crossref.org/works/10.1016%2FS1096-6374%2803%2900029-7

7 January 2021

New approach to the diagnosis of growth hormone deficiency in adults

1 reference

https://api.crossref.org/works/10.1016%2FS1096-6374%2803%2900029-7

7 January 2021

Growth hormone response to thyrotropin-releasing hormone and oral glucose-loading tests in tall children and adolescents

1 reference

https://api.crossref.org/works/10.1016%2FS1096-6374%2803%2900029-7

7 January 2021

An amplitude-specific divergence in the pulsatile mode of growth hormone (GH) secretion underlies the gender difference in mean GH concentrations in men and premenopausal women.

1 reference

https://api.crossref.org/works/10.1016%2FS1096-6374%2803%2900029-7

7 January 2021

Effects of sex and age on the 24-hour profile of growth hormone secretion in man: importance of endogenous estradiol concentrations

1 reference

https://api.crossref.org/works/10.1016%2FS1096-6374%2803%2900029-7

7 January 2021

Contrasting effects of oral and transdermal routes of estrogen replacement therapy on 24-hour growth hormone (GH) secretion, insulin-like growth factor I, and GH-binding protein in postmenopausal women

1 reference

https://api.crossref.org/works/10.1016%2FS1096-6374%2803%2900029-7

7 January 2021

The insulin-like growth factor-I system and hormone replacement therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1096-6374%2803%2900029-7

7 January 2021

The Relationship between Serum GH and Serum IGF-I in Acromegaly Is Gender-Specific

1 reference

https://api.crossref.org/works/10.1016%2FS1096-6374%2803%2900029-7

7 January 2021

Interactions between serum leptin, the insulin-like growth factor-I system, and sex, age, anthropometric and body composition variables in a healthy population randomly selected

1 reference

https://api.crossref.org/works/10.1016%2FS1096-6374%2803%2900029-7

7 January 2021

Use of the oral glucose tolerance test to define remission in acromegaly.

1 reference

https://api.crossref.org/works/10.1016%2FS1096-6374%2803%2900029-7

7 January 2021

Uremia reduces serum insulin-like growth factor I, increases insulin-like growth factor II, and modifies their serum protein binding

1 reference

https://api.crossref.org/works/10.1016%2FS1096-6374%2803%2900029-7

7 January 2021

Serum-free insulin-like growth factor I correlates with clearance in patients with chronic renal failure.

1 reference

https://api.crossref.org/works/10.1016%2FS1096-6374%2803%2900029-7

7 January 2021

Acromegaly or chronic renal failure: a diagnostic dilemma

1 reference

https://api.crossref.org/works/10.1016%2FS1096-6374%2803%2900029-7

7 January 2021

Serum insulin-like growth factors and their binding proteins in patients with hepatic failure and after liver transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS1096-6374%2803%2900029-7

7 January 2021

Elevated serum growth hormone in a patient with Type 1 diabetes: a diagnostic dilemma

1 reference

https://api.crossref.org/works/10.1016%2FS1096-6374%2803%2900029-7

7 January 2021

Commercial assays available for insulin-like growth factor I and their use in diagnosing growth hormone deficiency

1 reference

https://api.crossref.org/works/10.1016%2FS1096-6374%2803%2900029-7

7 January 2021

Is the measurement of free IGF-I more indicative than that of total IGF-I in the evaluation of the biological activity of the GH/IGF-I axis?

1 reference

https://api.crossref.org/works/10.1016%2FS1096-6374%2803%2900029-7

7 January 2021

Usefulness of Different Biochemical Markers of the Insulin-Like Growth Factor (IGF) Family in Diagnosing Growth Hormone Excess and Deficiency in Adults

1 reference

https://api.crossref.org/works/10.1016%2FS1096-6374%2803%2900029-7

7 January 2021

Free insulin-like growth factors (IGF-I and IGF-II) in human serum.

1 reference

https://api.crossref.org/works/10.1016%2FS1096-6374%2803%2900029-7

7 January 2021

A comparison of different methods for diagnosing acromegaly

1 reference

https://api.crossref.org/works/10.1016%2FS1096-6374%2803%2900029-7

7 January 2021

Total and free insulin-like growth factor I, insulin-like growth factor binding protein 3 and acid-labile subunit reflect clinical activity in acromegaly

1 reference

https://api.crossref.org/works/10.1016%2FS1096-6374%2803%2900029-7

7 January 2021

Investigation protocol: acromegaly and its investigation

1 reference

https://api.crossref.org/works/10.1016%2FS1096-6374%2803%2900029-7

7 January 2021

Diagnosis and endocrine testing in acromegaly.

1 reference

https://api.crossref.org/works/10.1016%2FS1096-6374%2803%2900029-7

7 January 2021

Normal control of growth hormone secretion

1 reference

https://api.crossref.org/works/10.1016%2FS1096-6374%2803%2900029-7

7 January 2021

Outpatient assessment of residual growth hormone secretion in treated acromegaly with overnight urinary growth hormone excretion, random serum growth hormone and insulin like growth factor-1.

1 reference

https://api.crossref.org/works/10.1016%2FS1096-6374%2803%2900029-7

7 January 2021

Criteria for cure of acromegaly: a consensus statement

1 reference

https://api.crossref.org/works/10.1016%2FS1096-6374%2803%2900029-7

7 January 2021

Insulin-like growth factor 1 measurement in diagnosis and management of acromegaly

1 reference

https://api.crossref.org/works/10.1016%2FS1096-6374%2803%2900029-7

7 January 2021

Assessment of growth hormone status in acromegaly: what biochemical markers to measure and how?

1 reference

https://api.crossref.org/works/10.1016%2FS1096-6374%2803%2900029-7

7 January 2021

Acromegaly. Recognition and treatment

1 reference

https://api.crossref.org/works/10.1016%2FS1096-6374%2803%2900029-7

7 January 2021

Growth hormone responses to oral glucose loading measured by highly sensitive enzyme immunoassay in normal subjects and patients with glucose intolerance and acromegaly

1 reference

https://api.crossref.org/works/10.1016%2FS1096-6374%2803%2900029-7

7 January 2021

Normal growth hormone response to the 75 g oral glucose tolerance test measured by immunoradiometric assay

1 reference

https://api.crossref.org/works/10.1016%2FS1096-6374%2803%2900029-7

7 January 2021

Effects of Estrogen and Sex Difference on Secretion of Human Growth Hormone1

1 reference

https://api.crossref.org/works/10.1016%2FS1096-6374%2803%2900029-7

7 January 2021

The influence of age on the 24-hour integrated concentration of growth hormone in normal individuals

1 reference

https://api.crossref.org/works/10.1016%2FS1096-6374%2803%2900029-7

7 January 2021

Preoperative growth hormone response to thyrotropin-releasing hormone and oral glucose tolerance test in acromegaly: a retrospective evaluation of 50 patients

1 reference

https://api.crossref.org/works/10.1016%2FS1096-6374%2803%2900029-7

7 January 2021

Variability in the quantitation of circulating growth hormone using commercial immunoassays

1 reference

https://api.crossref.org/works/10.1016%2FS1096-6374%2803%2900029-7

7 January 2021

Variable estimates of serum growth hormone concentrations by different radioassay systems

1 reference

https://api.crossref.org/works/10.1016%2FS1096-6374%2803%2900029-7

7 January 2021

Variety in growth hormone determinations due to use of different immunoassays and to the interference of growth hormone-binding protein

1 reference

https://api.crossref.org/works/10.1016%2FS1096-6374%2803%2900029-7

7 January 2021

Serum growth hormone measurements in clinical practice: An audit of performance from the UK National External Quality Assessment scheme

1 reference

https://api.crossref.org/works/10.1016%2FS1096-6374%2803%2900029-7

7 January 2021

International standards for growth hormone

1 reference

https://api.crossref.org/works/10.1016%2FS1096-6374%2803%2900029-7

7 January 2021

Consensus on how to measure growth hormone in serum

1 reference

https://api.crossref.org/works/10.1016%2FS1096-6374%2803%2900029-7

7 January 2021

Impairment of Hyperglycemic Induced Growth Hormone Suppression in Hyperthyroidism

1 reference

https://api.crossref.org/works/10.1016%2FS1096-6374%2803%2900029-7

7 January 2021

Paradoxical elevation of growth hormone in active chronic hepatitis

1 reference

https://api.crossref.org/works/10.1016%2FS1096-6374%2803%2900029-7

7 January 2021

Defective suppression of growth hormone after oral glucose loading in adolescence

1 reference

https://api.crossref.org/works/10.1016%2FS1096-6374%2803%2900029-7

7 January 2021

Suppression of Growth Hormone by Oral Glucose in the Evaluation of Tall Stature

1 reference

https://api.crossref.org/works/10.1016%2FS1096-6374%2803%2900029-7

7 January 2021

Determinants of clinical outcome and survival in acromegaly

1 reference

https://api.crossref.org/works/10.1016%2FS1096-6374%2803%2900029-7

7 January 2021

Mortality and cancer incidence in acromegaly: a retrospective cohort study. United Kingdom Acromegaly Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS1096-6374%2803%2900029-7

7 January 2021

Predictors of the Outcome of Surgical Treatment in Acromegaly and the Value of the Mean Growth Hormone Day Curve in Assessing Postoperative Disease Activity

1 reference

https://api.crossref.org/works/10.1016%2FS1096-6374%2803%2900029-7

7 January 2021

Use of Insulin-Like Growth Factor-Binding Protein 3 for the Evaluation of Growth Disorders

1 reference

https://api.crossref.org/works/10.1016%2FS1096-6374%2803%2900029-7

7 January 2021

Radioimmunoassay of growth hormone-dependent insulinlike growth factor binding protein in human plasma

1 reference

https://api.crossref.org/works/10.1016%2FS1096-6374%2803%2900029-7

7 January 2021

The ratio between serum levels of insulin-like growth factor (IGF)-I and the IGF binding proteins (IGFBP-1, 2 and 3) decreases with age in healthy adults and is increased in acromegalic patients

1 reference

https://api.crossref.org/works/10.1016%2FS1096-6374%2803%2900029-7

7 January 2021

Insulin-like growth factors (IGF)-I and -II and IGF binding protein-1, -2, and -3 in patients with acromegaly before and after adenomectomy

1 reference

https://api.crossref.org/works/10.1016%2FS1096-6374%2803%2900029-7

7 January 2021

Findings and theoretical considerations on the usefulness of the acid-labile subunit in the monitoring of acromegaly

1 reference

https://api.crossref.org/works/10.1016%2FS1096-6374%2803%2900029-7

7 January 2021

Circulating levels and molecular distribution of the acid-labile (alpha) subunit of the high molecular weight insulin-like growth factor-binding protein complex

1 reference

https://api.crossref.org/works/10.1016%2FS1096-6374%2803%2900029-7

7 January 2021

Diagnostic value of the acid-labile subunit in acromegaly: evaluation in comparison with insulin-like growth factor (IGF) I, and IGF-binding protein-1, -2, and -3.

1 reference

https://api.crossref.org/works/10.1016%2FS1096-6374%2803%2900029-7

7 January 2021

Acid-labile subunit in growth hormone excess and deficiency in adults: evaluation of its diagnostic value in comparison with insulin-like growth factor (IGF)-I and IGF-binding protein-3

1 reference

https://api.crossref.org/works/10.1016%2FS1096-6374%2803%2900029-7

7 January 2021

Postoperative persistent thyrotrophin releasing hormone-induced growth hormone release predicts recurrence in patients with acromegaly

1 reference

https://api.crossref.org/works/10.1016%2FS1096-6374%2803%2900029-7

7 January 2021

Acromegaly due to secretion of growth hormone by an ectopic pancreatic islet-cell tumor

1 reference

https://api.crossref.org/works/10.1016%2FS1096-6374%2803%2900029-7

7 January 2021

Somatotroph hyperplasia. Successful treatment of acromegaly by removal of a pancreatic islet tumor secreting a growth hormone-releasing factor

1 reference

https://api.crossref.org/works/10.1016%2FS1096-6374%2803%2900029-7

7 January 2021

Growth hormone-releasing hormone-producing tumors: clinical, biochemical, and morphological manifestations

1 reference

https://api.crossref.org/works/10.1016%2FS1096-6374%2803%2900029-7

7 January 2021

10.1016/S1096-6374(03)00029-7

Identifiers

DOI

1 reference

7 August 2017

1 reference